Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma

References

• Diagnosis and Management of Difficult-to-treat and Severe Asthma [Internet]. Global Initiative for Asthma - GINA. Available from: https://ginasthma.org/severeasthma/ [last accessed 23 August 2019].
   Google Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373. doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Passalacqua G. Anti-interleukin 5 therapies in severe asthma. Lancet Respir Med. 2017;5:537–538. doi:10.1016/S2213-2600(17)30206-0.
   PubMed Web of Science ®Google Scholar
• Dorman SC, Efthimiadis A, Babirad I, Watson RM, Denburg JA, Hargreave FE, O'Byrne PM, Sehmi R. Sputum CD34 + IL-5Ralpha + cells increase after allergen: evidence for. Am J Respir Crit Care Med. 2004;169:573–577. doi:10.1164/rccm.200307-1004OC.
   PubMed Web of Science ®Google Scholar
• Wood LJ, Sehmi R, Dorman S, Hamid Q, Tulic MK, Watson RM, Foley R, Wasi P, Denburg JA, Gauvreau G, et al. Allergen-induced increases in bone marrow T lymphocytes and interleukin-5 expression in subjects with asthma. Am J Respir Crit Care Med. 2002;166:883–889. doi:10.1164/rccm.2108015.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. DDDT 2017;11:3137–3144. doi:10.2147/DDDT.S150656.
   PubMed Web of Science ®Google Scholar
• Lopez AF, Begley CG, Williamson DJ, Warren DJ, Vadas MA, Sanderson CJ. Murine eosinophil differentiation factor. An eosinophil-specific colony-stimulating factor with activity for human cells. J Exp Med. 1986;163:1085–1099. doi:10.1084/jem.163.5.1085.
   PubMed Web of Science ®Google Scholar
• Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet 2015;386:1086–1096. doi:10.1016/S0140-6736(15)00157-9.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–984. doi:10.1056/NEJMoa0808991.
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MMM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–993. doi:10.1056/NEJMoa0805435.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet Lond Engl. 2012; 380:651–659. doi:10.1016/S0140-6736(12)60988-X.
   PubMed Web of Science ®Google Scholar
• Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834. Available from: doi:10.1002/14651858.CD010834.pub3.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Lond Engl. 2016;388:2128–2141. doi:10.1016/S0140-6736(16)31322-8.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet Lond Engl. 2016;388:2115–2127. doi:10.1016/S0140-6736(16)31324-1.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355–366. doi:10.1016/S2213-2600(15)00042-9.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 2016;150:789–798. doi:10.1016/j.chest.2016.03.032.
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, Boulet L-P, Xie F, Young J, Wilkins HJ, Henkel T, Nair P. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125–1132. doi:10.1164/rccm.201103-0396OC.
   PubMed Web of Science ®Google Scholar
• Roufosse FE, Kahn J-E, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013;131:461–467.e1–5. doi:10.1016/j.jaci.2012.07.055.
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38:2058–2070.e1. doi:10.1016/j.clinthera.2016.07.010.
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Caminati M, Ferrando M, Aloè T, Testino E, Canonica GW, Passalacqua G. Anti-IL-5 and IL-5Ra: efficacy and safety of new therapeutic strategies in severe uncontrolled asthma. BioMed Res Int. 2018;2018:1. doi:10.1155/2018/5698212.
   Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143:1742–1751.e7. doi:10.1016/j.jaci.2018.09.033.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M, Yañez A, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7:46–59. doi:10.1016/S2213-2600(18)30406-5.
   PubMed Web of Science ®Google Scholar
• Murphy K, Jacobs J, Bjermer L, Fahrenholz JM, Shalit Y, Garin M, Zangrilli J, Castro M. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017;5:1572–1581.e3. doi:10.1016/j.jaip.2017.08.024.
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon H-U, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358:1215–1228. doi:10.1056/NEJMoa070812.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921–1932. doi:10.1056/NEJMoa1702079.
   PubMed Web of Science ®Google Scholar